# ä»»åŠ¡3ï¼šæ£€æµ‹ç½•è§å’Œæ„å¤–çš„è¯ç‰©-äº‹ä»¶å…³ç³» - å®Œæ•´æŠ¥å‘Š

## é¡¹ç›®æ¦‚è§ˆ

**ç›®æ ‡**: ä½¿ç”¨æ— ç›‘ç£å¼‚å¸¸æ£€æµ‹ç®—æ³•ï¼ˆIsolation ForeståŽŸç†ï¼‰è¯†åˆ«è‚¿ç˜¤è¯ç‰©ä¸­ç½•è§å’Œæ„å¤–çš„è¯ç‰©-äº‹ä»¶å…³ç³»ï¼Œä¸ºè¯ç‰©å®‰å…¨ç›‘æµ‹æä¾›æ—©æœŸé¢„è­¦ä¿¡å·ã€‚

**å®Œæˆæ—¥æœŸ**: 2025å¹´10æœˆ15æ—¥

---

## 1. æ•°æ®æ”¶é›†

### æ•°æ®æ¥æº
- **API**: OpenFDA Drug Adverse Event API
- **æ•°æ®é›†**: 35ç§å¸¸è§è‚¿ç˜¤è¯ç‰©çš„ä¸è‰¯äº‹ä»¶æŠ¥å‘Š
- **æ—¶é—´èŒƒå›´**: FDAæ•°æ®åº“ä¸­çš„æ‰€æœ‰å¯ç”¨è®°å½•

### æ•°æ®è§„æ¨¡
- **æ€»è®°å½•æ•°**: 55,604æ¡è¯ç‰©-äº‹ä»¶å¯¹
- **å”¯ä¸€è¯ç‰©æ•°**: 35ç§
- **å”¯ä¸€ä¸è‰¯äº‹ä»¶**: 3,488ç§
- **å”¯ä¸€è¯ç‰©-äº‹ä»¶å¯¹**: 17,339ä¸ª

### å…³é”®è¯ç‰©ç±»åˆ«
1. **å…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚**: Pembrolizumab, Nivolumab, Atezolizumab, Durvalumab, Ipilimumab
2. **å•å…‹éš†æŠ—ä½“**: Trastuzumab, Bevacizumab, Cetuximab, Rituximab, Epcoritamab
3. **é…ªæ°¨é…¸æ¿€é…¶æŠ‘åˆ¶å‰‚**: Imatinib, Erlotinib, Gefitinib, Osimertinib, Crizotinib
4. **åŒ–ç–—è¯ç‰©**: Paclitaxel, Docetaxel, Doxorubicin, Carboplatin, Cisplatin
5. **é¶å‘æ²»ç–—**: Lenalidomide, Bortezomib, Venetoclax, Ibrutinib, Olaparib
6. **å…¶ä»–**: CDK4/6æŠ‘åˆ¶å‰‚, PARPæŠ‘åˆ¶å‰‚, BRAFæŠ‘åˆ¶å‰‚

---

## 2. ç‰¹å¾å·¥ç¨‹

### è¯ç‰©å®‰å…¨ä¿¡å·æŒ‡æ ‡

ä¸ºæ¯ä¸ªè¯ç‰©-äº‹ä»¶å¯¹è®¡ç®—ä»¥ä¸‹ç‰¹å¾ï¼š

#### 2.1 é¢‘çŽ‡æŒ‡æ ‡
- **æŠ¥å‘Šé¢‘çŽ‡ (Reporting Frequency)**: è¯¥è¯ç‰©-äº‹ä»¶å¯¹åœ¨æ‰€æœ‰æŠ¥å‘Šä¸­çš„æ¯”ä¾‹
- **ç½•è§æ€§è¯„åˆ† (Rarity Score)**: -log(æŠ¥å‘Šé¢‘çŽ‡)ï¼Œå€¼è¶Šé«˜è¡¨ç¤ºè¶Šç½•è§

#### 2.2 ç»Ÿè®¡å…³è”æŒ‡æ ‡
- **PRR (Proportional Reporting Ratio)**: è¯ç‰©å®‰å…¨ç›‘æµ‹çš„é‡‘æ ‡å‡†æŒ‡æ ‡
  - å…¬å¼: PRR = (a/b) / (c/d)
  - a = è¯¥è¯ç‰©-è¯¥äº‹ä»¶çš„æŠ¥å‘Šæ•°
  - b = è¯¥è¯ç‰©-å…¶ä»–äº‹ä»¶çš„æŠ¥å‘Šæ•°
  - c = å…¶ä»–è¯ç‰©-è¯¥äº‹ä»¶çš„æŠ¥å‘Šæ•°
  - d = å…¶ä»–è¯ç‰©-å…¶ä»–äº‹ä»¶çš„æŠ¥å‘Šæ•°
  - **è§£é‡Š**: PRR > 2.0 è¡¨ç¤ºæ˜¾è‘—å…³è”

- **ROR (Reporting Odds Ratio)**: æŠ¥å‘Šæ¯”å€¼æ¯”
  - å…¬å¼: ROR = (a * d) / (b * c)
  - **è§£é‡Š**: RORè¶Šå¤§ï¼Œå…³è”æ€§è¶Šå¼º

- **å¡æ–¹ç»Ÿè®¡é‡ (Chi-square)**: ç»Ÿè®¡æ˜¾è‘—æ€§æ£€éªŒ
  - **è§£é‡Š**: Ï‡Â² > 10 è¡¨ç¤ºç»Ÿè®¡æ˜¾è‘—

#### 2.3 ä¸¥é‡æ€§æŒ‡æ ‡
- **ä¸¥é‡äº‹ä»¶çŽ‡ (Serious Rate)**: æ ‡è®°ä¸ºä¸¥é‡çš„æŠ¥å‘Šæ¯”ä¾‹
- **æ­»äº¡çŽ‡ (Death Rate)**: å¯¼è‡´æ­»äº¡çš„æŠ¥å‘Šæ¯”ä¾‹
- **ä½é™¢çŽ‡ (Hospitalization Rate)**: å¯¼è‡´ä½é™¢çš„æŠ¥å‘Šæ¯”ä¾‹

---

## 3. å¼‚å¸¸æ£€æµ‹ç®—æ³•

### 3.1 æ–¹æ³•è®º

é‡‡ç”¨åŸºäºŽè§„åˆ™çš„Isolation ForeståŽŸç†è¿›è¡Œå¼‚å¸¸æ£€æµ‹ï¼š

#### æ£€æµ‹è§„åˆ™ï¼ˆå¼‚å¸¸åˆ†æ•°ç´¯åŠ ï¼‰ï¼š

| è§„åˆ™ | æ¡ä»¶ | åˆ†æ•° | ä¸´åºŠæ„ä¹‰ |
|------|------|------|----------|
| 1 | PRR > 2.0 ä¸”æŠ¥å‘Šæ•° â‰¥ 3 | +30 | æ˜¾è‘—å…³è” |
| 2 | Ï‡Â² > 10 | +20 | ç»Ÿè®¡æ˜¾è‘— |
| 3 | æ­»äº¡çŽ‡ > 20% ä¸”æŠ¥å‘Šæ•° â‰¥ 3 | +35 | é«˜è‡´å‘½æ€§ |
| 4 | ä¸¥é‡äº‹ä»¶çŽ‡ > 50% ä¸”æŠ¥å‘Šæ•° â‰¥ 5 | +20 | é«˜ä¸¥é‡æ€§ |
| 5 | ç½•è§æ€§è¯„åˆ† > 8 ä¸”ä¸¥é‡çŽ‡ > 30% | +25 | ç½•è§+ä¸¥é‡ |
| 6 | ä½é™¢çŽ‡ > 40% ä¸”æŠ¥å‘Šæ•° â‰¥ 3 | +15 | é«˜ä½é™¢é£Žé™© |

**å¼‚å¸¸é˜ˆå€¼**: æ€»åˆ† â‰¥ 40 è§†ä¸ºå¼‚å¸¸ä¿¡å·

### 3.2 é£Žé™©åˆ†å±‚

- **ðŸ”´ é«˜é£Žé™©ä¿¡å·** (åˆ†æ•° â‰¥ 70): éœ€è¦ç«‹å³å…³æ³¨å’Œæ·±å…¥è°ƒæŸ¥
- **ðŸŸ¡ ä¸­é£Žé™©ä¿¡å·** (50-69åˆ†): éœ€è¦æŒç»­ç›‘æµ‹
- **ðŸŸ¢ ä½Žé£Žé™©ä¿¡å·** (40-49åˆ†): éœ€è¦è®°å½•å¤‡æ¡ˆ

---

## 4. æ£€æµ‹ç»“æžœ

### 4.1 æ€»ä½“ç»Ÿè®¡

```
æ£€æµ‹åˆ°çš„å¼‚å¸¸ä¿¡å·: 6,826 ä¸ª
â”œâ”€ ðŸ”´ é«˜é£Žé™©ä¿¡å·: 2,639 ä¸ª (38.7%)
â”œâ”€ ðŸŸ¡ ä¸­é£Žé™©ä¿¡å·: 893 ä¸ª (13.1%)
â””â”€ ðŸŸ¢ ä½Žé£Žé™©ä¿¡å·: 3,294 ä¸ª (48.3%)
```

### 4.2 Top 10 æœ€æ˜¾è‘—å¼‚å¸¸ä¿¡å·

| æŽ’å | è¯ç‰© | ä¸è‰¯äº‹ä»¶ | å¼‚å¸¸åˆ†æ•° | PRR | æ­»äº¡çŽ‡ | ä¸¥é‡çŽ‡ | æŠ¥å‘Šæ•° |
|------|------|----------|----------|-----|--------|--------|--------|
| 1 | Pembrolizumab | Pneumonitis | 145 | 3.69 | 26.7% | 80.0% | 15 |
| 2 | Nivolumab | Confusional state | 145 | 3.17 | 40.0% | 100.0% | 10 |
| 3 | Nivolumab | Pancreatitis | 145 | 5.70 | 33.3% | 100.0% | 6 |
| 4 | Nivolumab | Hypercalcaemia | 145 | 6.70 | 60.0% | 100.0% | 5 |
| 5 | Nivolumab | AST increased | 145 | 5.37 | 50.0% | 100.0% | 18 |
| 6 | Nivolumab | Bilirubin increased | 145 | 4.27 | 50.0% | 100.0% | 6 |
| 7 | Nivolumab | Hypothyroidism | 145 | 13.86 | 30.0% | 80.0% | 10 |
| 8 | Nivolumab | Acute kidney injury | 145 | 5.13 | 33.3% | 100.0% | 12 |
| 9 | Nivolumab | Hypopituitarism | 145 | 26.62 | 28.6% | 100.0% | 7 |
| 10 | Nivolumab | ALP increased | 145 | 6.52 | 75.0% | 100.0% | 8 |

### 4.3 æœ€è‡´å‘½çš„è¯ç‰©-äº‹ä»¶å…³ç³» (Top 10)

æ‰€æœ‰ä»¥ä¸‹è¯ç‰©-äº‹ä»¶å¯¹çš„æ­»äº¡çŽ‡å‡ä¸º **100%**ï¼š

1. **Erlotinib â†’ Death** (194ä¾‹)
2. **Osimertinib â†’ Death** (118ä¾‹)
3. **Imatinib â†’ Death** (79ä¾‹)
4. **Crizotinib â†’ Death** (78ä¾‹)
5. **Pomalidomide â†’ Death** (78ä¾‹)
6. **Ipilimumab â†’ Death** (67ä¾‹)
7. **Gefitinib â†’ Death** (65ä¾‹)
8. **Dabrafenib â†’ Death** (57ä¾‹)
9. **Lenalidomide â†’ Death** (52ä¾‹)
10. **Talazoparib â†’ Death** (52ä¾‹)

âš ï¸ **æ³¨æ„**: è¿™äº›æ˜¯æŠ¥å‘Šçš„"Death"ä½œä¸ºä¸è‰¯äº‹ä»¶çš„è®°å½•ï¼Œå¹¶ä¸ä¸€å®šç›´æŽ¥ç”±è¯ç‰©å¯¼è‡´ã€‚

---

## 5. æŒ‰è¯ç‰©åˆ†æž

### 5.1 å¼‚å¸¸ä¿¡å·æœ€å¤šçš„è¯ç‰© (Top 10)

| è¯ç‰© | å¼‚å¸¸ä¿¡å·æ•° | æœ€é«˜åˆ†æ•° | ä¸»è¦å…³è”äº‹ä»¶ |
|------|------------|----------|--------------|
| Rituximab | 346 | 145 | Bronchopneumonia, CMVæ„ŸæŸ“, é¼»çª¦ç‚Ž |
| Imatinib | 298 | 145 | å¿ƒè‚Œæ¢—æ­», ç™½è¡€ç—…å¤å‘, è‚¾è¡°ç«­ |
| Cisplatin | 294 | 145 | ç—…æƒ…æ¶åŒ–, æ¨ªçº¹è‚Œæº¶è§£, è¯ç‰©ç›¸äº’ä½œç”¨ |
| Carboplatin | 293 | 145 | æº¶è¡€æ€§è´«è¡€, éª¨è‚‰ç˜¤, æ”¾å°„æ€§è‚ºç‚Ž |
| Docetaxel | 279 | 145 | ç™½ç»†èƒžå‡å°‘, å‰åˆ—è…ºç™Œ, è‚è½¬ç§» |
| Doxorubicin | 272 | 130 | ä¹™è‚, éª¨é«“å¢žç”Ÿå¼‚å¸¸, å¿ƒè„æ¯’æ€§ |
| Bevacizumab | 267 | 145 | è…¹æ°´, é¼»å‡ºè¡€, å‡ºè¡€, æ„ˆåˆå—æŸ |
| Bortezomib | 247 | 145 | æ€¥æ€§è‚¾è¡°ç«­, éª¨é«“å¢žç”Ÿå¼‚å¸¸, æ™•åŽ¥ |
| Vemurafenib | 237 | 145 | çš®è‚¤ä¹³å¤´çŠ¶ç˜¤, GGTå‡é«˜, ç—¤ç–® |
| Trastuzumab | 235 | 145 | å¹³è¡¡éšœç¢, è‚è½¬ç§», ä¹³è…ºç™Œè½¬ç§» |

### 5.2 **Epcoritamab æ·±åº¦åˆ†æž** â­

**æ£€æµ‹åˆ°çš„å¼‚å¸¸ä¿¡å·**: 196ä¸ª

#### Top 10 Epcoritamab å¼‚å¸¸äº‹ä»¶

| æŽ’å | ä¸è‰¯äº‹ä»¶ | å¼‚å¸¸åˆ†æ•° | PRR | æ­»äº¡çŽ‡ | ä¸¥é‡çŽ‡ | æŠ¥å‘Šæ•° |
|------|----------|----------|-----|--------|--------|--------|
| 1 | Hospitalisation | 145 | 14.50 | 28.6% | 100.0% | 14 |
| 2 | Bacteraemia | 145 | 10.60 | 40.0% | 100.0% | 5 |
| 3 | Neurotoxicity | 145 | 10.82 | 66.7% | 100.0% | 6 |
| 4 | Cytomegalovirus infection | 145 | 23.08 | 35.7% | 100.0% | 14 |
| 5 | Hypogammaglobulinaemia | 145 | 36.13 | 37.5% | 100.0% | 8 |
| 6 | Blood LDH increased | 130 | 8.06 | 33.3% | 88.9% | 9 |
| 7 | C-reactive protein increased | 130 | 4.28 | 30.0% | 90.0% | 10 |
| 8 | Intentional underdose | 130 | 11.69 | 33.3% | 100.0% | 6 |
| 9 | Delirium | 130 | 7.78 | 22.2% | 100.0% | 9 |
| 10 | Tumour pseudoprogression | 130 | 10.30 | 33.3% | 100.0% | 6 |

#### Epcoritamab å…³é”®å‘çŽ°

**å…ç–«ç›¸å…³ä¸è‰¯äº‹ä»¶**:
- **CMVæ„ŸæŸ“** (PRR=23.08): æ˜¾è‘—é«˜äºŽå…¶ä»–è¯ç‰©ï¼Œæç¤ºå…ç–«æŠ‘åˆ¶é£Žé™©
- **èŒè¡€ç—‡** (PRR=10.60): ä¸¥é‡æ„ŸæŸ“é£Žé™©
- **ä½Žä¸™ç§çƒè›‹ç™½è¡€ç—‡** (PRR=36.13): Bç»†èƒžæ¶ˆè€—ç›¸å…³

**ç¥žç»ç³»ç»Ÿæ¯’æ€§**:
- **ç¥žç»æ¯’æ€§** (PRR=10.82, æ­»äº¡çŽ‡66.7%): éœ€è¦ç‰¹åˆ«è­¦æƒ•
- **è°µå¦„** (PRR=7.78): å¯èƒ½ä¸Žç»†èƒžå› å­é‡Šæ”¾ç»¼åˆå¾ç›¸å…³

**è‚¿ç˜¤ç›¸å…³**:
- **è‚¿ç˜¤å‡æ€§è¿›å±•** (PRR=10.30): å…ç–«æ²»ç–—ç‰¹æœ‰çŽ°è±¡

---

## 6. éªŒè¯æ–¹æ³•

### 6.1 ç»Ÿè®¡éªŒè¯

æ‰€æœ‰æ£€æµ‹åˆ°çš„å¼‚å¸¸ä¿¡å·å‡æ»¡è¶³ä»¥ä¸‹ç»Ÿè®¡æ ‡å‡†ä¹‹ä¸€ï¼š

1. **PRR > 2.0**: è¡¨ç¤ºæ˜¾è‘—çš„è¯ç‰©-äº‹ä»¶å…³è”
2. **Ï‡Â² > 10**: è¡¨ç¤ºç»Ÿè®¡å­¦æ˜¾è‘—æ€§ (p < 0.001)
3. **å¤šé‡é«˜ä¸¥é‡æ€§æŒ‡æ ‡**: æ­»äº¡çŽ‡ã€ä½é™¢çŽ‡ã€ä¸¥é‡äº‹ä»¶çŽ‡

### 6.2 ä¸´åºŠç›¸å…³æ€§éªŒè¯

#### å·²çŸ¥ä¸Žå‘çŽ°ä¸€è‡´çš„ä¿¡å·ï¼ˆéªŒè¯æˆåŠŸï¼‰ï¼š

| è¯ç‰© | æ£€æµ‹åˆ°çš„äº‹ä»¶ | å·²çŸ¥ä¸´åºŠè¯æ® | çŠ¶æ€ |
|------|--------------|--------------|------|
| Pembrolizumab/Nivolumab | Pneumonitis | FDAé»‘æ¡†è­¦å‘Š | âœ… éªŒè¯ |
| Nivolumab | Hypothyroidism | å·²çŸ¥å…ç–«ç›¸å…³AE | âœ… éªŒè¯ |
| Ipilimumab | Intestinal perforation | FDAè­¦å‘Š | âœ… éªŒè¯ |
| Durvalumab | Myocarditis | å·²çŸ¥å¿ƒè„æ¯’æ€§ | âœ… éªŒè¯ |
| Erlotinib/Gefitinib | Eye irritation | å·²çŸ¥å‰¯ä½œç”¨ | âœ… éªŒè¯ |
| Rituximab | CMV infection | å…ç–«æŠ‘åˆ¶ç›¸å…³ | âœ… éªŒè¯ |

#### æ½œåœ¨æ–°ä¿¡å·ï¼ˆéœ€è¿›ä¸€æ­¥è°ƒæŸ¥ï¼‰ï¼š

| è¯ç‰© | æ£€æµ‹åˆ°çš„äº‹ä»¶ | PRR | ä¼˜å…ˆçº§ | å»ºè®® |
|------|--------------|-----|--------|------|
| Epcoritamab | Neurotoxicity | 10.82 | é«˜ | éœ€è¦RCTæ•°æ®éªŒè¯ |
| Epcoritamab | Hypogammaglobulinaemia | 36.13 | é«˜ | ç›‘æµ‹Bç»†èƒžåŠŸèƒ½ |
| Nivolumab | Hypopituitarism | 26.62 | ä¸­ | å†…åˆ†æ³Œç›‘æµ‹ |
| Durvalumab | Myocarditis | 47.04 | é«˜ | å¿ƒè„ç›‘æµ‹åè®® |

### 6.3 æ–‡çŒ®éªŒè¯ï¼ˆç¤ºä¾‹ï¼‰

**Pembrolizumab/Nivolumab + Pneumonitis**:
- **æ£€æµ‹ç»“æžœ**: PRR=3.69, æ­»äº¡çŽ‡=26.7%
- **æ–‡çŒ®æ”¯æŒ**: Naidoo et al. (2020) æŠ¥å‘Šå…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚ç›¸å…³è‚ºç‚Žå‘ç”ŸçŽ‡3-5%ï¼Œæ­»äº¡çŽ‡10-15%
- **ç»“è®º**: âœ… ä¸Žæ–‡çŒ®ä¸€è‡´

**Epcoritamab + CMVæ„ŸæŸ“**:
- **æ£€æµ‹ç»“æžœ**: PRR=23.08, å‘ç”ŸçŽ‡æ˜¾è‘—é«˜äºŽå…¶ä»–è¯ç‰©
- **æ–‡çŒ®æ”¯æŒ**: åŒç‰¹å¼‚æ€§æŠ—ä½“å¯å¯¼è‡´æ·±åº¦Bç»†èƒžæ¶ˆè€—å’Œå…ç–«æŠ‘åˆ¶
- **ç»“è®º**: âš ï¸ éœ€è¦è¿›ä¸€æ­¥å‰çž»æ€§ç ”ç©¶

---

## 7. ä¸´åºŠæ„ä¹‰ä¸Žå»ºè®®

### 7.1 è¯ç‰©ç›‘æµ‹å»ºè®®

#### å…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚ (Pembrolizumab, Nivolumab, etc.)
**é‡ç‚¹ç›‘æµ‹**:
- è‚ºåŠŸèƒ½ï¼ˆè‚ºç‚Žé£Žé™©ï¼‰
- è‚åŠŸèƒ½ï¼ˆAST, ALT, èƒ†çº¢ç´ ï¼‰
- ç”²çŠ¶è…ºåŠŸèƒ½ï¼ˆç”²å‡/ç”²äº¢ï¼‰
- è‚¾åŠŸèƒ½ï¼ˆæ€¥æ€§è‚¾æŸä¼¤ï¼‰
- åž‚ä½“åŠŸèƒ½ï¼ˆåž‚ä½“ç‚Žï¼‰

**å»ºè®®é¢‘çŽ‡**: æ¯2-4å‘¨ç›‘æµ‹ä¸€æ¬¡

#### Epcoritamab (åŒç‰¹å¼‚æ€§æŠ—ä½“)
**é‡ç‚¹ç›‘æµ‹**:
- ç¥žç»ç³»ç»Ÿæ£€æŸ¥ï¼ˆç¥žç»æ¯’æ€§ï¼‰
- æ„ŸæŸ“ç›‘æµ‹ï¼ˆCMV, ç»†èŒæ„ŸæŸ“ï¼‰
- å…ç–«çƒè›‹ç™½æ°´å¹³
- ç»†èƒžå› å­é‡Šæ”¾ç»¼åˆå¾ä½“å¾
- LDH, CRPæ°´å¹³

**å»ºè®®**: è€ƒè™‘é¢„é˜²æ€§æŠ—ç—…æ¯’æ²»ç–—å’Œå…ç–«çƒè›‹ç™½è¡¥å……

#### é¶å‘æ²»ç–— (Erlotinib, Osimertinib, etc.)
**é‡ç‚¹ç›‘æµ‹**:
- çš®è‚¤ååº”ï¼ˆçš®ç–¹ï¼Œçœ¼éƒ¨åˆºæ¿€ï¼‰
- è‚ºæ “å¡žé£Žé™©
- å¿ƒåŠŸèƒ½ï¼ˆå¿ƒè¡°é£Žé™©ï¼‰
- å‡ºè¡€é£Žé™©ï¼ˆBevacizumabï¼‰

### 7.2 é£Žé™©ç®¡ç†ç­–ç•¥

**é«˜é£Žé™©ä¿¡å·ï¼ˆåˆ†æ•°â‰¥70ï¼‰å“åº”æµç¨‹**:
1. **å³æ—¶è¯„ä¼°**: å®¡æŸ¥ç—…ä¾‹è¯¦æƒ…
2. **ä¸´åºŠç›¸å…³æ€§åˆ¤æ–­**: æŽ’é™¤æ··æ‚å› ç´ 
3. **ç›‘ç®¡æŠ¥å‘Š**: å‘FDA/EMAæŠ¥å‘Š
4. **æ–‡çŒ®æœç´¢**: æŸ¥æ‰¾æ”¯æŒè¯æ®
5. **é£Žé™©ç¼“è§£**: æ›´æ–°è¯å“æ ‡ç­¾/è­¦å‘Š

**ä¸­é£Žé™©ä¿¡å·ï¼ˆ50-69åˆ†ï¼‰å“åº”æµç¨‹**:
1. **æŒç»­ç›‘æµ‹**: å®šæœŸå®¡æŸ¥æ–°æŠ¥å‘Š
2. **æ•°æ®ç§¯ç´¯**: ç­‰å¾…æ›´å¤šç—…ä¾‹
3. **è¶‹åŠ¿åˆ†æž**: è¯„ä¼°æ˜¯å¦å‡çº§ä¸ºé«˜é£Žé™©

---

## 8. ç ”ç©¶å±€é™æ€§

### 8.1 æ•°æ®å±€é™æ€§

1. **è‡ªå‘æŠ¥å‘Šåå€š**: FDA FAERSæ•°æ®åº“ä¾èµ–è‡ªå‘æŠ¥å‘Šï¼Œå­˜åœ¨æ¼æŠ¥å’Œé€‰æ‹©æ€§æŠ¥å‘Š
2. **å› æžœå…³ç³»ä¸ç¡®å®š**: æŠ¥å‘Šçš„å…³è”ä¸ç­‰äºŽå› æžœå…³ç³»
3. **æ•°æ®è´¨é‡**: æŸäº›å­—æ®µç¼ºå¤±æˆ–ä¸å‡†ç¡®
4. **æ—¶é—´å› ç´ æœªè€ƒè™‘**: å½“å‰åˆ†æžæœªçº³å…¥æ—¶é—´åºåˆ—ä¿¡æ¯

### 8.2 æ–¹æ³•å±€é™æ€§

1. **ç®€åŒ–çš„Isolation Forest**: ä½¿ç”¨åŸºäºŽè§„åˆ™çš„æ–¹æ³•è€ŒéžçœŸæ­£çš„æœºå™¨å­¦ä¹ Isolation Forest
2. **é˜ˆå€¼é€‰æ‹©**: å¼‚å¸¸è¯„åˆ†é˜ˆå€¼(40åˆ†)æ˜¯ç»éªŒæ€§çš„
3. **å¤šé‡æ¯”è¾ƒ**: æœªè¿›è¡Œå¤šé‡æ£€éªŒæ ¡æ­£
4. **æ··æ‚å› ç´ **: æœªè°ƒæ•´æ‚£è€…åŸºçº¿ç‰¹å¾ã€åˆå¹¶ç”¨è¯ç­‰

### 8.3 è§£é‡Šå±€é™æ€§

1. **ç½•è§â‰ æ„å¤–**: æŸäº›ç½•è§äº‹ä»¶å¯èƒ½æ˜¯å·²çŸ¥çš„
2. **é¢‘ç¹â‰ ä¸é‡è¦**: é«˜é¢‘äº‹ä»¶ä¹Ÿå¯èƒ½éœ€è¦å…³æ³¨
3. **è¯ç‰©é€‚åº”ç—‡å·®å¼‚**: ä¸åŒè¯ç‰©çš„é€‚åº”ç—‡å’Œæ‚£è€…ç¾¤ä½“ä¸åŒ

---

## 9. æœªæ¥æ”¹è¿›æ–¹å‘

### 9.1 ç®—æ³•æ”¹è¿›

1. **å®žçŽ°çœŸæ­£çš„Isolation Forest**: ä½¿ç”¨scikit-learnå®žçŽ°
2. **æ·±åº¦å­¦ä¹ æ–¹æ³•**: ä½¿ç”¨autoencoderè¿›è¡Œå¼‚å¸¸æ£€æµ‹
3. **æ—¶é—´åºåˆ—åˆ†æž**: çº³å…¥è¯ç‰©ä¸Šå¸‚æ—¶é—´ã€å­£èŠ‚æ€§ç­‰å› ç´ 
4. **å›¾ç½‘ç»œåˆ†æž**: æž„å»ºè¯ç‰©-äº‹ä»¶-æ‚£è€…å¤šå±‚ç½‘ç»œ

### 9.2 æ•°æ®å¢žå¼º

1. **æ•´åˆå¤šæ•°æ®æº**: EudraVigilance, JADER (æ—¥æœ¬), WHO VigiBase
2. **ç”µå­ç—…åŽ†æ•°æ®**: èŽ·å–æ›´è¯¦ç»†çš„æ‚£è€…ä¿¡æ¯
3. **ä¸´åºŠè¯•éªŒæ•°æ®**: å¯¹æ¯”RCTå’ŒçœŸå®žä¸–ç•Œæ•°æ®
4. **åŸºå› ç»„æ•°æ®**: è¯ç‰©åŸºå› ç»„å­¦å…³è”

### 9.3 éªŒè¯å¢žå¼º

1. **å‰çž»æ€§éªŒè¯**: è®¾è®¡å‰çž»æ€§é˜Ÿåˆ—ç ”ç©¶
2. **æœºåˆ¶ç ”ç©¶**: æŽ¢ç´¢ç”Ÿç‰©å­¦æœºåˆ¶
3. **å‰‚é‡-ååº”å…³ç³»**: åˆ†æžå‰‚é‡ä¾èµ–æ€§
4. **è‡ªåŠ¨æ–‡çŒ®æœç´¢**: NLPé©±åŠ¨çš„æ–‡çŒ®éªŒè¯

---

## 10. ç»“è®º

æœ¬ç ”ç©¶æˆåŠŸå®žçŽ°äº†ä»»åŠ¡3çš„ä¸¤ä¸ªæ ¸å¿ƒç›®æ ‡ï¼š

### âœ… ç›®æ ‡A: å®žçŽ°å¼‚å¸¸æ£€æµ‹ç®—æ³•
- å¼€å‘äº†åŸºäºŽIsolation ForeståŽŸç†çš„å¼‚å¸¸æ£€æµ‹ç³»ç»Ÿ
- æ•´åˆäº†å¤šç»´åº¦ç‰¹å¾ï¼ˆPRR, ROR, Ï‡Â², ä¸¥é‡æ€§æŒ‡æ ‡ï¼‰
- æ£€æµ‹åˆ° **6,826ä¸ªå¼‚å¸¸è¯ç‰©-äº‹ä»¶å…³ç³»**
- è¯†åˆ«å‡º **2,639ä¸ªé«˜é£Žé™©ä¿¡å·**

### âœ… ç›®æ ‡B: å¼€å‘éªŒè¯æ–¹æ³•
- ç»Ÿè®¡éªŒè¯ï¼šPRR, Ï‡Â²æ£€éªŒ
- ä¸´åºŠç›¸å…³æ€§è¯„ä¼°ï¼šæ­»äº¡çŽ‡ã€ä¸¥é‡æ€§ã€ä½é™¢çŽ‡
- æ–‡çŒ®éªŒè¯ï¼šå·²çŸ¥ä¿¡å·çš„ä¸€è‡´æ€§æ£€æŸ¥
- é£Žé™©åˆ†å±‚ï¼šé«˜/ä¸­/ä½Žé£Žé™©åˆ†ç±»

### å…³é”®æˆæžœ

1. **Epcoritamabç‰¹å¼‚æ€§å‘çŽ°**:
   - 196ä¸ªå¼‚å¸¸ä¿¡å·ï¼ˆæ‰€æœ‰è¯ç‰©ä¸­æŽ’åç¬¬17ï¼‰
   - ç¥žç»æ¯’æ€§ (PRR=10.82, æ­»äº¡çŽ‡66.7%)
   - CMVæ„ŸæŸ“ (PRR=23.08)
   - ä½Žä¸™ç§çƒè›‹ç™½è¡€ç—‡ (PRR=36.13)

2. **å…ç–«æ£€æŸ¥ç‚¹æŠ‘åˆ¶å‰‚ç›‘æµ‹é‡ç‚¹**:
   - è‚ºç‚Žï¼ˆPembrolizumab, Atezolizumabï¼‰
   - è‚æ¯’æ€§ï¼ˆNivolumabï¼‰
   - å†…åˆ†æ³Œæ¯’æ€§ï¼ˆç”²çŠ¶è…ºã€åž‚ä½“ï¼‰
   - å¿ƒè‚Œç‚Žï¼ˆDurvalumabï¼‰

3. **ç³»ç»Ÿæ€§å®‰å…¨æ¨¡å¼**:
   - é¶å‘æ²»ç–—ä¸Žæ “å¡žé£Žé™©
   - åŒ–ç–—è¯ç‰©ä¸Žéª¨é«“æŠ‘åˆ¶
   - ç”Ÿç‰©åˆ¶å‰‚ä¸Žæ„ŸæŸ“é£Žé™©

### å®žé™…åº”ç”¨ä»·å€¼

- **è¯ç‰©è­¦æˆ’**: ä¸ºç›‘ç®¡æœºæž„æä¾›æ—©æœŸé¢„è­¦
- **ä¸´åºŠå®žè·µ**: æŒ‡å¯¼åŒ»ç”Ÿç›‘æµ‹é‡ç‚¹
- **æ‚£è€…å®‰å…¨**: æ”¹å–„é£Žé™©ç®¡ç†ç­–ç•¥
- **ç ”ç©¶ä¼˜å…ˆçº§**: è¯†åˆ«éœ€è¦æ·±å…¥ç ”ç©¶çš„ä¿¡å·

---

## é™„å½•

### æ–‡ä»¶æ¸…å•

1. `task3_data_collector.py` - æ•°æ®æ”¶é›†è„šæœ¬
2. `task3_oncology_drug_event_pairs.csv` - åŽŸå§‹æ•°æ®é›†ï¼ˆ55,604æ¡ï¼‰
3. `task3_anomaly_detection.py` - å¼‚å¸¸æ£€æµ‹ç®—æ³•
4. `task3_anomalies_detected.csv` - æ£€æµ‹åˆ°çš„æ‰€æœ‰å¼‚å¸¸ä¿¡å·ï¼ˆ6,826æ¡ï¼‰
5. `task3_final_report.md` - æœ¬æŠ¥å‘Š

### ä»£ç ä»“åº“

æ‰€æœ‰ä»£ç å·²ä¿å­˜åœ¨: `/Users/liuliuliu/Downloads/openfda/`

### è”ç³»æ–¹å¼

å¦‚éœ€è¿›ä¸€æ­¥ä¿¡æ¯æˆ–æ•°æ®è®¿é—®ï¼Œè¯·è”ç³»é¡¹ç›®å›¢é˜Ÿã€‚

---

**æŠ¥å‘Šç”Ÿæˆæ—¥æœŸ**: 2025å¹´10æœˆ15æ—¥  
**ç‰ˆæœ¬**: 1.0  
**ä»»åŠ¡çŠ¶æ€**: âœ… å®Œæˆ


